[{"id":"cea531ae-4a8d-42a3-bdf5-0c58b57c4230","acronym":"","url":"https://clinicaltrials.gov/study/NCT05293964","created_at":"2022-03-24T13:52:35.533Z","updated_at":"2024-07-02T16:35:46.971Z","phase":"Phase 1","brief_title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05293964","lead_sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • SCR-6852"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/08/2025","study_completion_date":" 09/08/2025","last_update_posted":"2023-05-29"}]